Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130952 | 0.88 | NAMPT (0.45) | ALDH1A1MAPTSMN1; SMN2HPGDHTT | |
| SCHEMBL10132306 | 0.84 | MAPT (0.54) | LMNAALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL10130949 | 0.82 | MAPT (0.49) | MAPTSMN1; SMN2HTT | |
| SCHEMBL10130944 | 0.82 | TDP1 (0.50) | ALDH1A1MAPTSMN1; SMN2ALOX12 | |
| SCHEMBL10130940 | 0.81 | GAA (0.49) | MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL10130959 | 0.80 | MEN1 (0.57) | LMNAALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL4075128 | 0.80 | KCNH2 (0.52) | MGLL | |
| SCHEMBL6003339 | 0.80 | KCNH2 (0.52) | MGLL | |
| SCHEMBL6002385 | 0.80 | KCNH2 (0.52) | MGLL | |
| SCHEMBL14615319 | 0.80 | KCNH2 (0.52) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | LMNA 3476/4885ALDH1A1 295/4885MAPT 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.